Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Krishna Pandey
Total Records ( 2 ) for Krishna Pandey
  Jayati Mookerjee Basu , Ananda Mookerjee , Rajdeep Banerjee , Manik Saha , Subhankar Singh , Ksudiram Naskar , Gayetri Tripathy , Prabhat K. Sinha , Krishna Pandey , Shyam Sundar , Sanjeev Bimal , Pradip K. Das , Soumitra K. Choudhuri and Syamal Roy
  The emergence of antimony (Sb) resistance has jeopardized the treatment of visceral leishmaniasis in various countries. Previous studies have considered the part played by leishmanial parasites in antimony resistance, but the involvement of host factors in the clinical scenario remained to be investigated. Here we show that unlike infection with Sb-sensitive (Sbs) Leishmania donovani, infection with Sb-resistant (Sbr) L. donovani induces the upregulation of multidrug resistance-associated protein 1 (MRP1) and permeability glycoprotein (P-gp) in host cells, resulting in a nonaccumulation of intracellular Sb following treatment with sodium antimony gluconate (SAG) favoring parasite replication. The inhibition of MRP1 and P-gp with resistance-modifying agents such as lovastatin allows Sb accumulation and parasite killing within macrophages and offers protection in an animal model in which infection with Sbr L. donovani is otherwise lethal. The occurrence of a similar scenario in clinical cases is supported by the findings that unlike monocytes from SAG-sensitive kala-azar (KA) patients, monocytes from SAG-unresponsive KA patients overexpress P-gp and MRP1 and fail to accumulate Sb following in vitro SAG treatment unless pretreated with inhibitors of ABC transporters. Thus, the expression status of MRP1 and P-gp in blood monocytes may be used as a diagnostic marker for Sb resistance and the treatment strategy can be designed accordingly. Our results also indicate that lovastatin, which can inhibit both P-gp and MRP1, might be beneficial for reverting Sb resistance in leishmaniasis as well as drug resistance in other clinical situations, including cancer.
  Krishna Murti , Manoj Kumar Sethi , Akalanka Dey , Chandra Sekhar Lal , Krishna Pandey and Pradeep Das
  This study compares the change in BMI, fasting and postprandial blood glucose, glycosylated haemoglobin (HbA1c), Glomerular Filtration Rate (GFR), serum creatinine, blood urea and lipid profile levels when two different therapies (group A = metformin+glimepiride) and group B = metformin+glimepiride+voglibose) are given to diabetic patients to compare efficacy of voglibose as an add-on therapy. This study was a 10 months prospective, open-label comparative study. Type II diabetic subjects, aged >18 years were selected and were divided into group A and B. All the parameters were evaluated before the treatment and reassessed after 3 months of treatment. Group A and B was having significant decrease in BMI with p<0.017 and p<0.049, respectively. In both of the groups glucose triad levels decreased significantly as p value found less than 0.05. There was no effect was found over blood urea level. Protective function of kidney observed when voglibose added. Evidence of controlling lipid profile also observed in triple drug therapy as p-value was <0.05. The add-on therapy using voglibose in dual therapy including glimepiride and metformin showed a very significant benefit in controlling the glucose triad levels (HbA1C, fasting plasma glucose and postprandial glucose level) when compared to dual therapy. Voglibose has an effect to decrease Total Cholesterol (TC), triglycerides (TGs) and Low Density Lipoproteins (LDL) level and increase HDL significantly. There was no effect was found on blood urea level.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility